Fred Saad
MD, FRCS
Meeting Chair
Institut du cancer de Montréal/CRCHUM
Meeting Chair
Institut du cancer de Montréal/CRCHUM
Kim Chi, MD
University of British Columbia
University of British Columbia
Andrew Loblaw, MD, FRCPC, MSc
University of Toronto
University of Toronto
Advances in the Diagnosis of Prostate Cancer
Peter Pinto
National Cancer Institute, National Institutes of Health in Bethesda, MD, USA Bio
National Cancer Institute, National Institutes of Health in Bethesda, MD, USA Bio
Dr. Pinto is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Md. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Dr. Pinto is a Board Certified Urologic Surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.
Introducer/Moderator: Frédéric Pouliot
Julian Kim
, MD, FRCPC
Department of Radiology, University of Manitoba
Department of Radiology, University of Manitoba
Peter Pinto
National Cancer Institute, National Institutes of Health in Bethesda, MD, USA
National Cancer Institute, National Institutes of Health in Bethesda, MD, USA
Bobby Shayegan, MD, FRCSC
Division of Urology, McMaster University
Division of Urology, McMaster University
Metastatic Castrate Sensitive Prostate Cancer
Alan So, MD
University of British Columbia Bio
University of British Columbia Bio
Dr. So’s current research focuses on the study of development of novel therapeutics for bladder cancer and determination of the functional role of GLI1/2 in the progression of prostate cancer to its lethal stage of androgen independence. He has characterized the functional role of different survival genes (including clusterin and Hsp27) in different tumor models (prostate, breast, lung, and bladder) in cancer progression. His current research focuses on discovery and development of novel agents to treat bladder cancer as well as development of the mechanisms of treatment resistance in renal cell carcinoma.
This web site is provided as a convenience to you and is for informational purposes only. The information on or available through this web site is not a substitute for professional medical care by a qualified doctor or other health care professional.
CUA Corporate Office
185 Dorval Avenue, Suite 401
Dorval, Quebec H9S 5J9
Tel: +1 514 395 0376
Fax: +1 514 395 1664
This email address is being protected from spambots. You need JavaScript enabled to view it.
185 Dorval Avenue, Suite 401
Dorval, Quebec H9S 5J9
Tel: +1 514 395 0376
Fax: +1 514 395 1664
This email address is being protected from spambots. You need JavaScript enabled to view it.